TriNetX will link with Regeneron to provide the company exclusive, secure access to de-identified health data from approximately 300 million individuals, aimed at supporting drug discovery and development. The arrangement is positioned as a data-infrastructure upgrade, focusing on genomic and proteomic access pathways for translational studies. The move reflects a broader shift in which real-world and large-scale clinical datasets are being packaged for specific discovery use cases rather than general analytics. For Regeneron, it extends the company’s toolset for target validation, patient matching, and hypothesis generation. For biotech, partnerships like this can shorten the time from biomarker discovery to trial design, particularly where proteomic and genomic stratification is needed to support next cohorts or evidence packages.